GSK took rights to a cardiovascular siRNA program from China-based SiranBio, centered on ALK7 knockdown linked to reductions in visceral fat and cardiovascular risk markers. The agreement grants most global rights while excluding mainland China, Hong Kong, Macau, and Taiwan, where SiranBio retains control. The companies did not disclose the size of the upfront payment, but SiranBio said it is eligible for more than $1 billion in total payments plus royalties, indicating a milestone-heavy structure tied to development progress. The deal reinforces how major pharma continues to build RNAi franchises through target-driven partnerships, particularly where early clinical or translational signals suggest measurable cardio-metabolic effects.